ALCLS.PA实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 23:35):

Stats
今日成交量	544 296
平均成交量	88 753.00
市值	198.03M
EPS	$0 ( 2024-04-03 )
下一个收益日期	( $-0.300 ) 2024-06-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.530
ATR14	$0.0110 (0.37%)

音量相关性

長: 0.26 (neutral)

短: -0.46 (neutral)

Signal:(54.33) Neutral

Cellectis SA 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cellectis SA 相关性 - 货币/商品

-0.32
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.30
( neutral )

0.29
( neutral )

Cellectis SA 财务报表

Annual	2023
营收:	$755 000
毛利润:	$18 000.00 (2.38 %)
EPS:	$-1.770

FY	2023
营收:	$755 000
毛利润:	$18 000.00 (2.38 %)
EPS:	$-1.770

FY	2022
营收:	$19.17M
毛利润:	$17.40M (90.76 %)
EPS:	$-2.17

FY	2021
营收:	$57.29M
毛利润:	$25.93M (45.26 %)
EPS:	$-1.910

Financial Reports:

No articles found.

Cellectis SA

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.